Ono Pharmaceutical (OTCMKTS:OPHLF) Sees Large Volume Increase – What’s Next?

Ono Pharmaceutical Co. (OTCMKTS:OPHLF) shares saw unusually-high trading volume on Thursday . Approximately 1,111 shares changed hands during mid-day trading, an increase of 66% from the previous session’s volume of 671 shares.The stock last traded at $15.05 and had previously closed at $14.71.

Wall Street Analysts Forecast Growth

Separately, Zacks Research raised Ono Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research report on Monday, July 13th. One research analyst has rated the stock with a Strong Buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Strong Buy”.

Ono Pharmaceutical Stock Down 4.0%

The company has a debt-to-equity ratio of 0.10, a current ratio of 3.02 and a quick ratio of 2.56. The business has a 50 day simple moving average of $14.41 and a 200 day simple moving average of $14.80. The stock has a market cap of $7.07 billion, a PE ratio of 14.33 and a beta of 0.33.

About Ono Pharmaceutical

Ono Pharmaceutical Co, Ltd., founded in 1717 and headquartered in Osaka, Japan, is a research?based pharmaceutical company specializing in the discovery, development and marketing of innovative therapies. With origins as a traditional pharmacy, Ono has grown into a global biopharmaceutical entity focused on delivering new treatment options across several therapeutic areas, including oncology, immunology, cardiovascular and antiviral diseases. The company conducts comprehensive research programs spanning early drug discovery through to clinical development.

One of Ono’s most recognized products is the immune checkpoint inhibitor nivolumab, marketed in collaboration with Bristol-Myers Squibb under the trade name Opdivo.